Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?

Beck ACC, Kieffer JM, Retèl VP, van Overveld LFJ, Takes RP, van den Brekel MWM, van Harten WH, Stuiver MM.

PLoS One. 2019 Dec 13;14(12):e0226077. doi: 10.1371/journal.pone.0226077. eCollection 2019.

2.

Healthcare professionals' perspectives of barriers and facilitators in implementing physical activity programmes delivered to cancer survivors in a shared-care model: a qualitative study.

IJsbrandy C, van Harten WH, Gerritsen WR, Hermens RPMG, Ottevanger PB.

Support Care Cancer. 2019 Dec 2. doi: 10.1007/s00520-019-05108-1. [Epub ahead of print]

PMID:
31792881
3.

Barriers and facilitators of patient access to medical devices in Europe: A systematic literature review.

Beck A, Retèl VP, Bhairosing PA, van den Brekel M, van Harten WH.

Health Policy. 2019 Dec;123(12):1185-1198. doi: 10.1016/j.healthpol.2019.10.002. Epub 2019 Oct 19. Review.

PMID:
31718855
4.

Moderators of Exercise Effects on Cancer-related Fatigue: A Meta-analysis of Individual Patient Data.

VAN Vulpen JK, Sweegers MG, Peeters PHM, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, Galvão DA, Chinapaw MJ, Steindorf K, Irwin ML, Stuiver MM, Hayes S, Griffith KA, Mesters I, Knoop H, Goedendorp MM, Mutrie N, Daley AJ, McConnachie A, Bohus M, Thorsen L, Schulz KH, Short CE, James EL, Plotnikoff RC, Schmidt ME, Ulrich CM, VAN Beurden M, Oldenburg HS, Sonke GS, VAN Harten WH, Schmitz KH, Winters-Stone KM, Velthuis MJ, Taaffe DR, VAN Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Verdonck-DE Leeuw IM, Brug J, May AM, Buffart LM.

Med Sci Sports Exerc. 2020 Feb;52(2):303-314. doi: 10.1249/MSS.0000000000002154.

PMID:
31524827
5.

Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms.

Verbeek JGE, Atema V, Mewes JC, van Leeuwen M, Oldenburg HSA, van Beurden M, Hunter MS, van Harten WH, Aaronson NK, Retèl VP.

Breast Cancer Res Treat. 2019 Dec;178(3):573-585. doi: 10.1007/s10549-019-05410-w. Epub 2019 Aug 26.

6.

Adherence to and satisfaction with low-intensity physical activity and supervised moderate-high intensity exercise during chemotherapy for breast cancer.

van Waart H, Buffart LM, Stuiver MM, van Harten WH, Sonke GS, Aaronson NK.

Support Care Cancer. 2019 Aug 8. doi: 10.1007/s00520-019-05019-1. [Epub ahead of print]

PMID:
31396745
7.

Implementing physical activity programs for patients with cancer in current practice: patients' experienced barriers and facilitators.

IJsbrandy C, Hermens RPMG, Boerboom LWM, Gerritsen WR, van Harten WH, Ottevanger PB.

J Cancer Surviv. 2019 Oct;13(5):703-712. doi: 10.1007/s11764-019-00789-3. Epub 2019 Jul 25.

8.

Variation in the time to treatment for stage III and IV non-small cell lung cancer patients for hospitals in the Netherlands.

van de Ven M, Retèl VP, Koffijberg H, van Harten WH, IJzerman MJ.

Lung Cancer. 2019 Aug;134:34-41. doi: 10.1016/j.lungcan.2019.05.023. Epub 2019 May 21.

9.

Study protocol of a prospective multicenter study comparing (cost-)effectiveness of a tailored interdisciplinary head and neck rehabilitation program to usual supportive care for patients treated with concomitant chemo- or bioradiotherapy.

Beck ACC, Passchier E, Retèl VP, Stuiver MM, van der Molen L, Klop WMC, Navran A, van Harten WH, van den Brekel MWM.

BMC Cancer. 2019 Jul 3;19(1):655. doi: 10.1186/s12885-019-5874-z.

10.

Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial.

Koole SN, van Lieshout C, van Driel WJ, van Schagen E, Sikorska K, Kieffer JM, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AG, Verwaal VJ, Van de Vijver KK, Aaronson NK, van Tinteren H, Sonke GS, van Harten WH, Retèl VP.

J Clin Oncol. 2019 Aug 10;37(23):2041-2050. doi: 10.1200/JCO.19.00594. Epub 2019 Jun 28.

PMID:
31251694
11.

Impact of organ-on-a-chip technology on pharmaceutical R&D costs.

Franzen N, van Harten WH, Retèl VP, Loskill P, van den Eijnden-van Raaij J, IJzerman M.

Drug Discov Today. 2019 Sep;24(9):1720-1724. doi: 10.1016/j.drudis.2019.06.003. Epub 2019 Jun 8.

12.

Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.

van Waalwijk van Doorn-Khosrovani SB, Pisters-van Roy A, van Saase L, van der Graaff M, Gijzen J, Sleijfer S, Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, van der Velden DL, van Werkhoven E, Retel VP, van Harten WH, Huitema ADR, Timmers L, Gelderblom H, Verheul HMW, Voest EE.

Ann Oncol. 2019 May 1;30(5):663-665. doi: 10.1093/annonc/mdz119. No abstract available.

PMID:
31038154
13.

A duty to recontact in genetics: context matters.

Giesbertz NAA, van Harten WH, Bredenoord AL.

Nat Rev Genet. 2019 Jul;20(7):371-372. doi: 10.1038/s41576-019-0121-7. No abstract available.

PMID:
30932026
14.

Patient access to voice prostheses and heat and moisture exchangers: Factors influencing physician's prescription and reimbursement in eight European countries.

Beck ACC, Retèl VP, van den Brekel MWM, van Harten WH.

Oral Oncol. 2019 Apr;91:56-64. doi: 10.1016/j.oraloncology.2019.02.017. Epub 2019 Mar 1.

15.

Turning teams and pathways into integrated practice units: Appearance characteristics and added value.

van Harten WH.

Int J Care Coord. 2018 Dec;21(4):113-116. doi: 10.1177/2053434518816529. Epub 2018 Dec 14.

16.

(Cost-)effectiveness of an internet-based physical activity support program (with and without physiotherapy counselling) on physical activity levels of breast and prostate cancer survivors: design of the PABLO trial.

van de Wiel HJ, Stuiver MM, May AM, van Grinsven S, Aaronson NK, Retèl VP, Oldenburg HSA, van der Poel HG, Horenblas S, van Harten WH, Groen WG.

BMC Cancer. 2018 Nov 6;18(1):1073. doi: 10.1186/s12885-018-4927-z.

17.

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product.

Lindenberg MA, Retèl VP, van den Berg JH, Geukes Foppen MH, Haanen JB, van Harten WH.

J Immunother. 2018 Nov/Dec;41(9):413-425. doi: 10.1097/CJI.0000000000000245.

18.

Targeting Exercise Interventions to Patients With Cancer in Need: An Individual Patient Data Meta-Analysis.

Buffart LM, Sweegers MG, May AM, Chinapaw MJ, van Vulpen JK, Newton RU, Galvão DA, Aaronson NK, Stuiver MM, Jacobsen PB, Verdonck-de Leeuw IM, Steindorf K, Irwin ML, Hayes S, Griffith KA, Lucia A, Herrero-Roman F, Mesters I, van Weert E, Knoop H, Goedendorp MM, Mutrie N, Daley AJ, McConnachie A, Bohus M, Thorsen L, Schulz KH, Short CE, James EL, Plotnikoff RC, Arbane G, Schmidt ME, Potthoff K, van Beurden M, Oldenburg HS, Sonke GS, van Harten WH, Garrod R, Schmitz KH, Winters-Stone KM, Velthuis MJ, Taaffe DR, van Mechelen W, José Kersten M, Nollet F, Wenzel J, Wiskemann J, Brug J, Courneya KS.

J Natl Cancer Inst. 2018 Nov 1;110(11):1190-1200. doi: 10.1093/jnci/djy161.

19.

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation.

Retèl VP, Steuten LMG, Geukes Foppen MH, Mewes JC, Lindenberg MA, Haanen JBAG, van Harten WH.

BMC Cancer. 2018 Sep 15;18(1):895. doi: 10.1186/s12885-018-4788-5.

20.

Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data.

Sweegers MG, Altenburg TM, Brug J, May AM, van Vulpen JK, Aaronson NK, Arbane G, Bohus M, Courneya KS, Daley AJ, Galvao DA, Garrod R, Griffith KA, Van Harten WH, Hayes SC, Herrero-Román F, Kersten MJ, Lucia A, McConnachie A, van Mechelen W, Mutrie N, Newton RU, Nollet F, Potthoff K, Schmidt ME, Schmitz KH, Schulz KH, Sonke G, Steindorf K, Stuiver MM, Taaffe DR, Thorsen L, Twisk JW, Velthuis MJ, Wenzel J, Winters-Stone KM, Wiskemann J, Chin A Paw MJ, Buffart LM.

Br J Sports Med. 2019 Jul;53(13):812. doi: 10.1136/bjsports-2018-099191. Epub 2018 Sep 4.

PMID:
30181323
21.

Systematic review and meta-analysis of distance-based physical activity interventions for cancer survivors (2013-2018): We still haven't found what we're looking for.

Groen WG, van Harten WH, Vallance JK.

Cancer Treat Rev. 2018 Sep;69:188-203. doi: 10.1016/j.ctrv.2018.07.012. Epub 2018 Jul 21. Review.

PMID:
30077954
22.

Barriers and Facilitators Affecting Patient Portal Implementation from an Organizational Perspective: Qualitative Study.

Kooij L, Groen WG, van Harten WH.

J Med Internet Res. 2018 May 11;20(5):e183. doi: 10.2196/jmir.8989.

23.

What drives centralisation in cancer care?

Kilsdonk MJ, Siesling S, van Dijk BAC, Wouters MW, van Harten WH.

PLoS One. 2018 Apr 12;13(4):e0195673. doi: 10.1371/journal.pone.0195673. eCollection 2018.

24.

The use of advanced medical technologies at home: a systematic review of the literature.

Ten Haken I, Ben Allouch S, van Harten WH.

BMC Public Health. 2018 Feb 26;18(1):284. doi: 10.1186/s12889-018-5123-4. Review.

25.

Review: Effectiveness of implementation strategies to increase physical activity uptake during and after cancer treatment.

IJsbrandy C, Ottevanger PB, Tsekou Diogeni M, Gerritsen WR, van Harten WH, Hermens RPMG.

Crit Rev Oncol Hematol. 2018 Feb;122:157-163. doi: 10.1016/j.critrevonc.2017.09.005. Epub 2017 Sep 12. Review.

26.

Implementing large scale fast track diagnostics in a comprehensive cancer center, pre- and post-measurement data.

van Harten WH, Goedbloed N, Boekhout AH, Heintzbergen S.

BMC Health Serv Res. 2018 Feb 7;18(1):85. doi: 10.1186/s12913-018-2868-5.

27.

Value of Implementation of Strategies to Increase the Adherence of Health Professionals and Cancer Survivors to Guideline-Based Physical Exercise.

Mewes JC, Steuten LMG, IJsbrandy C, IJzerman MJ, van Harten WH.

Value Health. 2017 Dec;20(10):1336-1344. doi: 10.1016/j.jval.2017.04.013. Epub 2017 Jun 20.

28.

Recruitment to and pilot results of the PACES randomized trial of physical exercise during adjuvant chemotherapy for colon cancer.

van Waart H, Stuiver MM, van Harten WH, Geleijn E, de Maaker-Berkhof M, Schrama J, Geenen MM, Meerum Terwogt JM, van den Heiligenberg SM, Hellendoorn-van Vreeswijk JAJH, Sonke GS, Aaronson NK.

Int J Colorectal Dis. 2018 Jan;33(1):29-40. doi: 10.1007/s00384-017-2921-6. Epub 2017 Nov 9.

PMID:
29124329
29.

Cost-utility and cost-effectiveness of physical exercise during adjuvant chemotherapy.

van Waart H, van Dongen JM, van Harten WH, Stuiver MM, Huijsmans R, Hellendoorn-van Vreeswijk JAJH, Sonke GS, Aaronson NK.

Eur J Health Econ. 2018 Jul;19(6):893-904. doi: 10.1007/s10198-017-0936-0. Epub 2017 Oct 30.

PMID:
29086085
30.

A SYSTEMATIC APPROACH FOR ASSESSING, IN THE ABSENCE OF FULL EVIDENCE, WHETHER MULTICOMPONENT INTERVENTIONS CAN BE MORE COST-EFFECTIVE THAN SINGLE COMPONENT INTERVENTIONS.

Mewes JC, Steuten LMG, IJzerman MJ, van Harten WH.

Int J Technol Assess Health Care. 2017 Jan;33(4):444-453. doi: 10.1017/S0266462317000721. Epub 2017 Sep 11.

PMID:
28889817
31.

Supporting Lung Cancer Patients With an Interactive Patient Portal: Feasibility Study.

Groen WG, Kuijpers W, Oldenburg HS, Wouters MW, Aaronson NK, van Harten WH.

JMIR Cancer. 2017 Aug 8;3(2):e10. doi: 10.2196/cancer.7443.

32.

The Effectiveness of Information Technology-Supported Shared Care for Patients With Chronic Disease: A Systematic Review.

Kooij L, Groen WG, van Harten WH.

J Med Internet Res. 2017 Jun 22;19(6):e221. doi: 10.2196/jmir.7405. Review.

33.

Assessing and comparing the quality of wound centres: a literature review and benchmarking pilot.

Pruim L, Wind A, van Harten WH.

Int Wound J. 2017 Dec;14(6):1120-1136. doi: 10.1111/iwj.12768. Epub 2017 Jun 13. Review.

PMID:
28612454
34.

eHealth for Breast Cancer Survivors: Use, Feasibility and Impact of an Interactive Portal.

Kuijpers W, Groen WG, Oldenburg HS, Wouters MW, Aaronson NK, van Harten WH.

JMIR Cancer. 2016 May 10;2(1):e3. doi: 10.2196/cancer.5456.

35.

Benchmarking specialty hospitals, a scoping review on theory and practice.

Wind A, van Harten WH.

BMC Health Serv Res. 2017 Apr 4;17(1):245. doi: 10.1186/s12913-017-2154-y. Review.

36.

Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review.

Lindenberg MA, Miquel-Cases A, Retèl VP, Sonke GS, Wesseling J, Stokkel MPM, van Harten WH.

Crit Rev Oncol Hematol. 2017 Apr;112:198-207. doi: 10.1016/j.critrevonc.2017.02.014. Epub 2017 Feb 17. Review.

PMID:
28325260
37.

Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs.

Buffart LM, Kalter J, Sweegers MG, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, May AM, Galvão DA, Chinapaw MJ, Steindorf K, Irwin ML, Stuiver MM, Hayes S, Griffith KA, Lucia A, Mesters I, van Weert E, Knoop H, Goedendorp MM, Mutrie N, Daley AJ, McConnachie A, Bohus M, Thorsen L, Schulz KH, Short CE, James EL, Plotnikoff RC, Arbane G, Schmidt ME, Potthoff K, van Beurden M, Oldenburg HS, Sonke GS, van Harten WH, Garrod R, Schmitz KH, Winters-Stone KM, Velthuis MJ, Taaffe DR, van Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Verdonck-de Leeuw IM, Brug J.

Cancer Treat Rev. 2017 Jan;52:91-104. doi: 10.1016/j.ctrv.2016.11.010. Epub 2016 Dec 5. Review.

38.
39.

(Very) Early technology assessment and translation of predictive biomarkers in breast cancer.

Miquel-Cases A, Schouten PC, Steuten LM, Retèl VP, Linn SC, van Harten WH.

Cancer Treat Rev. 2017 Jan;52:117-127. doi: 10.1016/j.ctrv.2016.11.008. Epub 2016 Nov 30. Review.

40.

Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis.

van Amerongen RA, Retèl VP, Coupé VM, Nederlof PM, Vogel MJ, van Harten WH.

Ecancermedicalscience. 2016 Oct 28;10:684. eCollection 2016.

41.
42.

Quality assessments for cancer centers in the European Union.

Wind A, Rajan A, van Harten WH.

BMC Health Serv Res. 2016 Sep 7;16:474. doi: 10.1186/s12913-016-1738-2.

43.

Cost-effectiveness and resource use of implementing MRI-guided NACT in ER-positive/HER2-negative breast cancers in The Netherlands.

Miquel-Cases A, Steuten LM, Rigter LS, van Harten WH.

BMC Cancer. 2016 Sep 5;16:712. doi: 10.1186/s12885-016-2653-y.

44.

Decisions on Further Research for Predictive Biomarkers of High-Dose Alkylating Chemotherapy in Triple-Negative Breast Cancer: A Value of Information Analysis.

Miquel-Cases A, Retèl VP, van Harten WH, Steuten LM.

Value Health. 2016 Jun;19(4):419-30. doi: 10.1016/j.jval.2016.01.015. Epub 2016 Apr 6.

45.

Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients.

Miquel-Cases A, Retèl VP, Lederer B, von Minckwitz G, Steuten LM, van Harten WH.

PLoS One. 2016 Apr 28;11(4):e0154386. doi: 10.1371/journal.pone.0154386. eCollection 2016.

46.

Co-creation of an ICT-supported cancer rehabilitation application for resected lung cancer survivors: design and evaluation.

Timmerman JG, Tönis TM, Dekker-van Weering MG, Stuiver MM, Wouters MW, van Harten WH, Hermens HJ, Vollenbroek-Hutten MM.

BMC Health Serv Res. 2016 Apr 27;16:155. doi: 10.1186/s12913-016-1385-7.

47.

Scenario drafting for early technology assessment of next generation sequencing in clinical oncology.

Joosten SEP, Retèl VP, Coupé VMH, van den Heuvel MM, van Harten WH.

BMC Cancer. 2016 Feb 6;16:66. doi: 10.1186/s12885-016-2100-0.

48.

Excellent translational research in oncology: A journey towards novel and more effective anti-cancer therapies.

Rajan A, Berns A, Ringborg U, Celis J, Ponder B, Caldas C, Livingston D, Bristow RG, Hecht TT, Tursz T, van Luenen H, Bono P, Helander T, Seamon K, Smyth JF, Louvard D, Eggermont A, van Harten WH.

Mol Oncol. 2016 May;10(5):645-51. doi: 10.1016/j.molonc.2015.12.007. Epub 2015 Dec 23. Review.

49.

Two decades of external peer review of cancer care in general hospitals; the Dutch experience.

Kilsdonk MJ, Siesling S, Otter R, van Harten WH.

Cancer Med. 2016 Mar;5(3):478-85. doi: 10.1002/cam4.612. Epub 2015 Dec 29.

50.

Actual costs of cancer drugs in 15 European countries.

van Harten WH, Wind A, de Paoli P, Saghatchian M, Oberst S.

Lancet Oncol. 2016 Jan;17(1):18-20. doi: 10.1016/S1470-2045(15)00486-6. Epub 2015 Dec 4. No abstract available.

PMID:
26670093

Supplemental Content

Loading ...
Support Center